Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$10.14 - $12.38 $34.4 Million - $42 Million
-3,390,406 Reduced 69.18%
1,510,792 $15.7 Million
Q2 2022

Aug 15, 2022

BUY
$11.05 - $12.72 $1.22 Million - $1.4 Million
110,002 Added 2.3%
4,901,198 $56.5 Million
Q1 2022

May 16, 2022

BUY
$10.61 - $12.88 $7.64 Million - $9.27 Million
719,934 Added 17.68%
4,791,196 $60.3 Million
Q4 2021

Feb 14, 2022

SELL
$10.86 - $13.95 $15.3 Million - $19.7 Million
-1,412,307 Reduced 25.76%
4,071,262 $47.5 Million
Q3 2021

Nov 15, 2021

BUY
$11.92 - $13.92 $8.89 Million - $10.4 Million
746,154 Added 15.75%
5,483,569 $71.6 Million
Q2 2021

Aug 16, 2021

BUY
$10.16 - $13.11 $14.1 Million - $18.2 Million
1,388,883 Added 41.48%
4,737,415 $61 Million
Q4 2020

Feb 16, 2021

BUY
$9.05 - $12.2 $11.3 Million - $15.3 Million
1,253,200 Added 59.81%
3,348,532 $38.1 Million
Q3 2020

Nov 16, 2020

BUY
$8.99 - $10.74 $1.82 Million - $2.17 Million
202,200 Added 10.68%
2,095,332 $18.8 Million
Q2 2020

Aug 14, 2020

BUY
$9.14 - $11.97 $765,932 - $1 Million
83,800 Added 4.63%
1,893,132 $19.5 Million
Q1 2020

May 15, 2020

BUY
$8.58 - $14.01 $15.5 Million - $25.3 Million
1,809,332 New
1,809,332 $18.3 Million
Q3 2019

Nov 14, 2019

SELL
$8.59 - $10.96 $2.97 Million - $3.79 Million
-345,600 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$9.8 - $12.89 $3.39 Million - $4.45 Million
345,600 New
345,600 $3.78 Million
Q4 2018

Feb 14, 2019

SELL
$7.8 - $16.13 $1.03 Million - $2.13 Million
-131,858 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$14.31 - $17.65 $818,360 - $1.01 Million
-57,188 Reduced 30.25%
131,858 $2.43 Million
Q2 2018

Aug 14, 2018

BUY
$11.83 - $16.2 $2.24 Million - $3.06 Million
189,046 New
189,046 $3.61 Million

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $539M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Putnam Investments LLC Portfolio

Follow Putnam Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Putnam Investments LLC with notifications on news.